Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | CCR5 | P51681 | 2/20 | 0.39 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.39 |
| ▸ | CALM1 | P0DP23 | 1/20 | 0.38 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.38 |
| ▸ | IDO1 | P14902 | 1/20 | 0.38 |
| ▸ | BCL2 | P10415 | 1/20 | 0.37 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23068287 | 0.78 | AKT2 (0.48) | TAAR1HRH3CCR5CXCR4CALM1 | |
| SCHEMBL13495318 | 0.75 | CCR5 (0.41) | TAAR1HRH3CCR5CXCR4HPGD | |
| SCHEMBL22547310 | 0.74 | NR1H2 (0.43) | TAAR1HRH3CALM1IDO1HPGD | |
| SCHEMBL13516287 | 0.74 | LMNA (0.48) | TAAR1HRH3CCR5CXCR4CALM1 | |
| SCHEMBL28340009 | 0.74 | CCR5 (0.47) | TAAR1HRH3CCR5CXCR4CALM1 | |
| SCHEMBL2374036 | 0.70 | AKT1 (0.58) | TRPA1MEN1KMT2A | |
| SCHEMBL14722889 | 0.69 | RNASEH1 (0.43) | BCL2BCL2L1HPGD | |
| SCHEMBL6548117 | 0.68 | HTR2A (0.56) | TP53CALM1BCL2BCL2L1TSHR | |
| SCHEMBL10824453 | 0.67 | TP53 (0.48) | TP53CALM1BCL2BCL2L1 | |
| SCHEMBL10234162 | 0.67 | GAA (0.51) | MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160318933-A1 | FUSED PYRAZOLE DERIVATIVE | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2016-11-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160318933-A1 | FUSED PYRAZOLE DERIVATIVE | DRD4, DRD2, DRD3 | TAAR1 147/4885HRH3 68/4885TP53 3036/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.